Evidence map›Paper›PMID 28440036›Full record

ArticleHIV medicine2017

A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada.

S Patterson, S Jose, H Samji, A Cescon, E Ding, J Zhu, J Anderson, A N Burchell, C Cooper, T Hill and 13 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. HIV and Aging: Reconsidering the Approach to Management of Comorbidities.Infectious disease clinics of North America · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 3 countries.

S PattersonBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
S JoseResearch Department of Infection and Population Health, University College London, London, UK.
H SamjiBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
A CesconBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
E DingBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
J ZhuBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
J AndersonHomerton University Hospital NHS Trust, London, UK.
A N BurchellDepartment of Family and Community Medicine, St Michael's Hospital, Toronto, ON, Canada.
C CooperThe Ottawa Hospital Division of Infectious Diseases, University of Ottawa, Ottawa, ON, Canada.
T HillResearch Department of Infection and Population Health, University College London, London, UK.
M HullBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
M B KleinFaculty of Medicine, McGill University, Montreal, QC, Canada.
M LoutfyFaculty of Medicine, University of Toronto, Toronto, ON, Canada.
F MartinYork Teaching Hospital NHS Foundation Trust, York, UK.
N MachoufClinique Medicale l'Actuel, Montreal, QC, Canada.
Jsg MontanerBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
M NelsonChelsea and Westminster Hospital NHS Trust, London, UK.
J RaboudDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
S B RourkeOntario HIV Treatment Network, Toronto, ON, Canada.
C TsoukasFaculty of Medicine, McGill University, Montreal, QC, Canada.
R S HoggBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
C SabinResearch Department of Infection and Population Health, University College London, London, UK.
Canadian Observational Cohort (CANOC) - UK Collaborative HIV Cohort (UK CHIC) Collaboration
AIDS Vancouver · CAUniversity College London · GBMcGill University · CASimon Fraser University · CAUniversity of Toronto · CABC Centre for Disease Control · CAChelsea and Westminster Hospital NHS Foundation Trust · GBClinique Claude-Bernard · FRHomerton University Hospital · GBNOSM University · CAOntario HIV Treatment Network · CAPublic Health Ontario · CAUniversity of British Columbia · CAUniversity of Ottawa · CAYork Teaching Hospital NHS Foundation Trust · GB

Funding

Seek and Treat for Optimal Outcomes and Prevention in HIV & AIDS in IDUDP1DA026182 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MONTANER, JULIO SERGIO GONZALEZ · 2008 to 2013
$3.9M
CIHRMedical Research Council G0600337Medical Research Council G0900274Medical Research Council MC_UU_12023/15NIDA NIH HHS DP1 DA026182
6 · The paper itself

Abstract

objectivesWe sought to compare all-cause mortality of people living with HIV and accessing care in Canada and the UK.

methodsIndividuals from the Canadian Observational Cohort (CANOC) collaboration and UK Collaborative HIV Cohort (UK CHIC) study who were aged ≥ 18 years, had initiated antiretroviral therapy (ART) for the first time between 2000 and 2012 and who had acquired HIV through sexual transmission were included in the analysis. Cox regression was used to investigate the difference in mortality risk between the two cohort collaborations, accounting for loss to follow-up as a competing risk.

resultsA total of 19 960 participants were included in the analysis (CANOC, 4137; UK CHIC, 15 823). CANOC participants were more likely to be older [median age 39 years (interquartile range (IQR): 33, 46 years) vs. 36 years (IQR: 31, 43 years) for UK CHIC participants], to be male (86 vs. 73%, respectively), and to report men who have sex with men (MSM) sexual transmission risk (72 vs. 56%, respectively) (all P < 0.001). Overall, 762 deaths occurred during 98 798 person-years (PY) of follow-up, giving a crude mortality rate of 7.7 per 1000 PY [95% confidence interval (CI): 7.1, 8.3 per 1000 PY]. The crude mortality rates were 8.6 (95% CI: 7.4, 10.0) and 7.5 (95% CI: 6.9, 8.1) per 1000 PY among CANOC and UK CHIC study participants, respectively. No statistically significant difference in mortality risk was observed between the cohort collaborations in Cox regression accounting for loss to follow-up as a competing risk (adjusted hazard ratio 0.86; 95% CI: 0.72-1.03).

conclusionsDespite differences in national HIV care provision and treatment guidelines, mortality risk did not differ between CANOC and UK CHIC study participants who acquired HIV through sexual transmission.

Indexed as

AdultAnti-HIV AgentsCanadaCohort StudiesFemaleHIV InfectionsHumansMaleMiddle AgedObservational Studies as TopicRisk FactorsSexually Transmitted Diseases, ViralUnited KingdomAnti-HIV AgentsAIDSantiretroviral therapyCanadaHIVmortalityUK

Identifiers

PMID28440036
PMCPMC5600099
OpenAlexW2609523462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.